Histogen

Histogen Corporate
Factsheet
Home > About Histogen > Management

Management
Gail K. Naughton, Ph.D., CEO

Gail K. NaughtonDr. Naughton has been the Dean of the College of Business Administration at San Diego State University since August 2002. Prior to that, she spent more than 15 years at Advanced Tissue Sciences, where she was the company's co-founder and co-inventor of its core technology. During her tenure there, Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist. gnaughton@histogeninc.com

James R. Goode, Acting CFO

James R. GoodeBringing extensive experience in hands-on CFO and financial management to HistoGen, Inc., James R. Goode provides guidance to emerging growth companies across a wide range of industries. Goode has over 30 years of consulting and senior management experience in helping organizations achieve their financial and operational goals, obtain funding, pursue acquisitions, expand their global business, and effect turnarounds.


Robert S. Kellar, Ph.D., Vice President Research and Development

Robert S. KellarDr. Kellar has more than 11 years of experience in research and product development. Dr. Kellar has joined Histogen from his positions as co-owner and President of Development Engineering Sciences, a firm based in Flagstaff, Arizona. Kellar's experience in the biomedical industry includes prior positions with W.L. Gore & Associates and Advanced Tissue Sciences, where he was involved with commercial worldwide management of research, product development, business, marketing, and sales.

Mark Baumgartner, Director of Engineering

Mark BaumgartnerMr. Baumgartner joined the company in 2007 with more than 20 years experience in product and process development for regulated biologic products. During 2006 and 2007 Mr. Baumgartner worked as a consultant to the biomedical and biopharmaceutical sectors on several projects for product development and process engineering. Mr. Baumgartner worked as Director of Process Development for Smith-Nephew Wound Management LLC, producing biological medical device products from 2002 to 2006. mbaumgartner@histogeninc.com

Beverly Dunlap, Director of Business Development

Beverly DunlapMs. Dunlap offers over 15 years experience in various aspects of the health industry. Experience in the private, government and non-profit sectors has given her a unique perspective to program and business development. With a background primarily in health and wellness, she ventured into health services administration when she moved to San Diego in 2000 after living in the Chicago and Washington, D.C. areas. bdunlap@histogeninc.com

Eileen Naughton, Director of Corporate Communications

Eileen NaughtonEileen brings more than 5 years of experience in communications and public relations to Histogen. Prior to joining Histogen in 2007, she held positions with Moore Media Relations, Inc., a firm working with high-technology companies throughout the U.S. on various PR projects, with a focus on media relations. Previously, Eileen held positions at San Diego State University's Entrepreneurial Management Center, beginning as a Student Assistant at the San Diego State University and later serving as Program Coordinator. enaughton@histogeninc.com

Frank Zeigler, General Manager of In Vitro Products

Frank ZeiglerFrank has more than 18 years of experience in research and product development, serving as senior scientist and project manager with biotechnology companies including Genentech, Advanced Tissue Sciences, and Stem Cells Inc. Recently, Frank was founder and CSO of Orion Biosolutions, a start-up biotech company, where he developed and brought research kit products to market. Currently, Frank is a consultant in cell-based product development. He has 8 peer-reviewed research publications and holds 3 issued US patents in the field of cell biology and cell analysis. fzeigler@histogeninc.com

Histogen Inc. is a regenerative medicine company based on the commercialization of products manufactured by newborn human fibroblasts.
  • Broad range of markets, which are underserved and expected to grow
  • Rich product portfolio
  • Solutions without the use of embryonic stem cells or animal products
© Histogen Inc., CA 92101